ForeSENTIA Tumour Profile
ForeSENTIA is a tumour profiling test for solid tumours that provides clinically relevant information to support treatment decision-making. It evaluates a range of genomic alterations and key biomarkers associated with targeted therapies and immunotherapies, enabling a more individualised approach to patient management.
The test is designed for patients who require additional guidance on therapeutic options, particularly in cases where standard treatments are limited, ineffective, or no longer provide benefit. By identifying molecular features of the tumour, ForeSENTIA helps inform the selection of therapies that are more likely to be effective for a specific patient.
The test provides clinically actionable insights by evaluating important biomarkers such as microsatellite instability (MSI) and tumour mutational burden (TMB), alongside genetic alterations – single nucleotide variants (SNVs), small insertions & deletions (INDELs), copy number alternations (CNVs), selected rearrangements, linked to available therapies and ongoing clinical trials. This allows healthcare providers to expand treatment possibilities and consider options tailored specifically to the patient’s tumour profile.
ForeSENTIA offers a flexible panel structure to address different clinical needs:
- 3 Pan-Cancer Tumour Profile panels, providing broad genomic coverage across multiple tumor types
- 6 Cancer-Specific panels, focused on genes relevant to particular cancer types
- 5 Gene-Focused panels, targeting key clinically actionable genes
A key advantage of ForeSENTIA is the integration of multiple clinically relevant analyses within a single test. In addition to identifying tumour-specific molecular characteristics, the report provides guidance on available treatment options and ongoing clinical trials, supporting a more precise and evidence-based approach to cancer care.
*ForeSENTIA does not diagnose cancer and is not a screening test. It cannot determine germline status. Possible hereditary implications require separate germline testing.
ForeSENTIA genetic tests
ForeSENTIA includes tumour genomic profiling panels designed to identify clinically actionable alterations across multiple cancer types. Selected panels evaluate genomic biomarkers relevant for immunotherapy such as tumour mutational burden (TMB) and microsatellite instability (MSI).
ForeSENTIA panels include:
- 3 Comprehensive tumour profile panels: Pan-Cancer Advanced, Pan-Cancer Plus and Pan-Cancer Core
- 6 Cancer-specific tumour profile panels: Breast/Gynecological, Colorectal, Glioma, Lung (NSCLC), Prostate, Melanoma
- 5 Gene-focused tumour profile panels: BRAF, EGFR, IDH1 & IDH2, KRAS & NRAS, PIK3CA & AKT
- testing of immunotherapy biomarkers MSI and TMB
Panel size varies depending on the selected test and may include extended gene coverage for comprehensive tumour profiling.
Benefits
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?
Certified laboratories
